WAVE LIFE SCIENCES LTD. Number of Reportable Segments
WAVE LIFE SCIENCES LTD. (WVE) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- WAVE LIFE SCIENCES LTD. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- WAVE LIFE SCIENCES LTD. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- WAVE LIFE SCIENCES LTD. number of reportable segments for fiscal 2024 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-07-30 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |